Sally Beauty Holdings Files Q1 2025 10-Q

TL;DR

**Sally Beauty Q1 2025 10-Q is in. Financials and ops detailed.**

AI Summary

Sally Beauty Holdings, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the first quarter of fiscal year 2025. Key financial data and business operations for this period are detailed, including sales revenue and administrative expenses. The company's fiscal year ends on September 30th.

Why It Matters

This filing provides investors with an update on Sally Beauty's financial performance and operational status for the first quarter of fiscal year 2025, impacting investment decisions.

Risk Assessment

Risk Level: medium — 10-Q filings are standard financial reports, but the specific details within can reveal risks related to sales, expenses, or market conditions.

Key Numbers

• 0930 — Fiscal Year End (Indicates the end of the company's annual accounting cycle.)
• 2024-12-31 — Period End Date (Marks the conclusion of the reporting quarter.)
• 2025-02-13 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

• Sally Beauty Holdings, Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of reporting period
• 2025-02-13 (date) — Filing date
• 0000950170-25-019869 (other) — Accession Number
• 3001 COLORADO BOULEVARD, DENTON, TX 76210 (address) — Company Business and Mail Address

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value SBH The New York Stock Ex

Filing Documents

• sbh-20241231.htm (10-Q) — 1626KB
• sbh-ex22.htm (EX-22) — 19KB
• sbh-ex31_1.htm (EX-31.1) — 18KB
• sbh-ex31_2.htm (EX-31.2) — 18KB
• sbh-ex32_1.htm (EX-32.1) — 10KB
• sbh-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-019869.txt ( ) — 6656KB
• sbh-20241231.xsd (EX-101.SCH) — 939KB
• sbh-20241231_htm.xml (XML) — 1117KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Earnings 5 Condensed Consolidated Statements of Comprehensive Income 6 Condensed Consolidated Statements of Stockholders' Equity 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 21

Controls and Procedures

Item 4. Controls and Procedures 21

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 22

Risk Factors

Item 1A. Risk Factors 22

Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities. 22

Other Information

Item 5. Other Information 22

Exhibits

Item 6. Exhibits 23 2 In this Quarterly Report, references to the "Company," "Sally Beauty," "our company," "we," "our," "ours" and "us" refer to Sally Beauty Holdings, Inc. and its consolidated subsidiaries unless otherwise indicated or the context otherwise requires. cautionary notice regarding forward-looking statements Readers are cautioned not to place undue reliance on forward-looking statements as such statements speak only as of the date they were made and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The most important factors which could cause our actual results to differ from our forward-looking statements are set forth in our description of risk factors in Item 1A contained in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024, which should be read in conjunction with the forward-looking statements in this report. Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update any forward-looking statement. The events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. As a result, our actual results may differ materially from the results contemplated by thes

— FINANCI AL INFORMATION

PART I — FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. SALLY BEAUTY HOLDINGS, INC. AND SUBSIDIARIES Condensed Consolidated Ba lance Sheets (In thousands, except par value data) December 31, 2024 September 30, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 105,528 $ 107,961 Trade accounts receivable, net 26,587 33,635 Accounts receivable, other 58,049 58,553 Inventory 1,005,975 1,036,624 Other current assets 50,581 68,541 Total current assets 1,246,720 1,305,314 Property and equipment, net of accumulated depreciation of $ 866,536 at December 31, 2024, and $ 881,818 at September 30, 2024 261,619 269,872 Operating lease assets 577,042 582,573 Goodwill 531,445 538,266 Intangible assets, excluding goodwill, net of accumulated amortization of $ 33,413 at December 31, 2024, and $ 33,761 at September 30, 2024 57,740 59,960 Other assets 36,202 36,914 Total assets $ 2,710,768 $ 2,792,899 Liabilities and Stockholders' Equity Current liabilities: Current maturities of long-term debt $ 4,079 $ 4,127 Accounts payable 220,650 269,424 Accrued liabilities 149,023 162,950 Current operating lease liabilities 152,365 136,068 Income taxes payable 22,482 20,100 Total current liabilities 548,599 592,669 Long-term debt 938,080 978,255 Long-term operating lease liabilities 456,672 479,616 Other liabilities 21,767 22,066 Deferred income tax liabilities, net 89,161 91,758 Total liabilities 2,054,279 2,164,364 Stockholders' equity: Common stock, $ 0.01 par value. Authorized 500,000 shares; 101,871 and 101,854 shares issued and shares outstanding at December 31, 2024, and September 30, 2024, respectively 1,019 1,019 Preferred stock, $ 0.01 par value. Authorized 50,000 shares; no ne issued — — Accumulated earnings 792,620 740,685 Accumulated other comprehensive loss, net of tax ( 137,150 ) ( 113,169 )

View Full Filing

View this 10-Q filing on SEC EDGAR